MedTrace Logo

Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer

NCT00006004 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-06-15

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective for treating non-small cell lung cancer.

PURPOSE: Randomized phase II trial to compare the effectiveness of two combination chemotherapy regimens in treating patients who have non-small cell lung cancer.

Conditions

Interventions

DRUG

carboplatin

DRUG

cisplatin

DRUG

gemcitabine hydrochloride

DRUG

paclitaxel

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Eastern Cooperative Oncology Group

    lead NETWORK

Principal Investigators

  • Corey J. Langer, MD · Fox Chase Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-08-22
Primary Completion
2005-01-31

Countries

  • United States
  • Australia
  • Peru
  • Puerto Rico

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00006004 on ClinicalTrials.gov